dc.contributor.author |
Adeleke, Oluwatoyin A
|
|
dc.contributor.author |
Tsai, P-C
|
|
dc.contributor.author |
Michniak-Kohn, BB
|
|
dc.date.accessioned |
2017-11-14T06:21:04Z |
|
dc.date.available |
2017-11-14T06:21:04Z |
|
dc.date.issued |
2015-10 |
|
dc.identifier.citation |
Adeleke, O.A., Tsai, P-C, and Michniak-Kohn, BB. 2015. Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide. In: American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Orlando, United States of America, October 25-29, 2015 |
en_US |
dc.identifier.uri |
http://abstracts.aaps.org/Verify/AAPS2015/PosterSubmissions/M1171.pdf
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/9766
|
|
dc.description |
American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Orlando, United States of America, October 25-29, 2015 |
en_US |
dc.description.abstract |
The purpose of this research is to prepare, characterize as well as assess the ex vivo buccal drug delivery and cytotoxicity of an orally disintegrating film (ODF) loaded with pyrazinamide. Pyrazinamide (solubility = 15 mg/mL at 25°C; log P = -1.884) is an antimicrobial agent indicated for the treatment of tuberculosis (TB) especially in HIV-infected persons with TB co-infection as well as for multidrug and extensively drug resistant TB. |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.ispartofseries |
Workflow;16576 |
|
dc.subject |
Antimicrobial agent |
en_US |
dc.subject |
Drug resistant tuberculosis |
en_US |
dc.subject |
Pyrazinamide |
en_US |
dc.title |
Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide |
en_US |
dc.type |
Conference Presentation |
en_US |
dc.identifier.apacitation |
Adeleke, O. A., Tsai, P., & Michniak-Kohn, B. (2015). Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide. http://hdl.handle.net/10204/9766 |
en_ZA |
dc.identifier.chicagocitation |
Adeleke, Oluwatoyin A, P-C Tsai, and BB Michniak-Kohn. "Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide." (2015): http://hdl.handle.net/10204/9766 |
en_ZA |
dc.identifier.vancouvercitation |
Adeleke OA, Tsai P, Michniak-Kohn B, Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide; 2015. http://hdl.handle.net/10204/9766 . |
en_ZA |
dc.identifier.ris |
TY - Conference Presentation
AU - Adeleke, Oluwatoyin A
AU - Tsai, P-C
AU - Michniak-Kohn, BB
AB - The purpose of this research is to prepare, characterize as well as assess the ex vivo buccal drug delivery and cytotoxicity of an orally disintegrating film (ODF) loaded with pyrazinamide. Pyrazinamide (solubility = 15 mg/mL at 25°C; log P = -1.884) is an antimicrobial agent indicated for the treatment of tuberculosis (TB) especially in HIV-infected persons with TB co-infection as well as for multidrug and extensively drug resistant TB.
DA - 2015-10
DB - ResearchSpace
DP - CSIR
KW - Antimicrobial agent
KW - Drug resistant tuberculosis
KW - Pyrazinamide
LK - https://researchspace.csir.co.za
PY - 2015
T1 - Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide
TI - Preparation, characterization and ex vivo evaluation of an orally disintegrating film formulation containing pyrazinamide
UR - http://hdl.handle.net/10204/9766
ER -
|
en_ZA |